TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02110979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of a PDA to assist shared decision making
Study: NCT02460289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment: Minoxidil 5% / Botanical Hair Solution for Men
Study: NCT04722406

Intervention type: OTHER
Intervention: This item is not applicable to our observational study.
Description: This item is not applicable to our observational study.

Intervention type: OTHER
Intervention: This item is not applicable to our observational study.
Description: This item is not applicable to our observational study.
Study: NCT03305718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 3C1A2B4D
Description: Participants receive test meals in the sequence 3C1A2B4D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 2A3D4C1B
Description: Participants receive test meals in the sequence 2A3D4C1B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 2D4B3A1C
Description: Participants receive test meals in the sequence 2D4B3A1C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 3B2C1D4A
Description: Participants receive test meals in the sequence 3B2C1D4A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 4C2B1A3D
Description: Participants receive test meals in the sequence 4C2B1A3D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence:1B4D3C2A
Description: Participants receive test meals in the sequence 1B4D3C2A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence:4A1C2D3B
Description: Participants receive test meals in the sequence 4A1C2D3B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence:1D3A4B2C
Description: Participants receive test meals in the sequence 1D3A4B2C
Study: NCT03760445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: 2.5 mg and 10mg capsules, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: 2.5 mg and 10mg capsules, given orally
Study: NCT03305718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 4D3B2C1A
Description: Participants receive test meals in the sequence 4D3B2C1A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 3A4C1B2D
Description: Participants receive test meals in the sequence 3A4C1B2D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 1C2A3D4B
Description: Participants receive test meals in the sequence 1C2A3D4B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 2B1D4A3C
Description: Participants receive test meals in the sequence 2B1D4A3C
Study: NCT01542762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
Study: NCT01298830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 CellBeads
Description: GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
Study: NCT00800046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch® Ventriculoplasty System
Description: Mitral valve repair due to functional disease
Study: NCT03638323

Intervention type: OTHER
Intervention: Speech therapy
Description: During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
Study: NCT05034549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: The non-invasive ventilator at home (≥5h/ night)
Study: NCT04509271

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs battery kits
Description: Novel peripheral blood diagnostic biomarker for MCI due to AD.

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs battery kits
Description: Novel peripheral blood diagnostic biomarker for MCI due to AD.

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs battery kits
Description: Novel peripheral blood diagnostic biomarker for MCI due to AD.

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs battery kits
Description: Novel peripheral blood diagnostic biomarker for MCI due to AD.

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs battery kits
Description: Novel peripheral blood diagnostic biomarker for MCI due to AD.

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs battery kits
Description: Novel peripheral blood diagnostic biomarker for MCI due to AD.

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs battery kits
Description: Novel peripheral blood diagnostic biomarker for MCI due to AD.
Study: NCT04040686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 99mTc-NM-02
Description: Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
Study: NCT04012528

Intervention type: OTHER
Intervention: ERAS program
Description: ERAS program
Study: NCT01625468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational print materials and a coaching call
Description: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
Study: NCT04237363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Underwater treadmill training and supplemental overground walk training
Study: NCT01066572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: 5-10 mg Lisinopril per day for seven days, depending on blood pressure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo; identical tablets to Lisinopril.
Study: NCT03279042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless corticotomy surgical intervention will be conducted
Description: Piezocision will be used to perform the procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional corticotomy
Description: Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
Study: NCT01950962

Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of blood

Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of blood

Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of blood
Study: NCT03087058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: 4.2 g/day, 8.4 g/day and 16.8 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: 2 g/day, 4 g/day and 8 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: 1 g/day, 2 g/day and 4 g/day
Study: NCT01376219

Intervention type: OTHER
Intervention: asthma control test
Description: results of asthma control testing collected
Study: NCT04344717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban single dose
Description: A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban single dose
Description: A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban single dose
Description: A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban steady-state
Description: Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban steady-state
Description: Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
Study: NCT01420536

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Occlusal scheme
Description: Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal scheme
Description: Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts.
Study: NCT00624988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibration Therapy
Description: Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
Study: NCT02911454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Study: NCT02941640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: E group
Description: The securing the base of appendix by endoloop.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: S group
Description: The securing the base of appendix by Stapler.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: H group
Description: The securing the base of appendix by Hem-o-lok clip.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DS group
Description: The securing the base of appendix by DS clip.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoloop

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stapler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hem-o-lok clip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS clip
Study: NCT01738100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study: NCT00988702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dan Tian Breathing
Description: Dan Tian Breathing for one month

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle training
Description: Progressive muscle training for one month
Study: NCT01628536

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black cohosh
Description: Remifemin 20 mg tablet orally twice per day x 4 weeks
Study: NCT02605200

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychologist Support
Description: Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pediatric Certified Diabetes Educators (CDEs) Support
Description: Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
Study: NCT03875001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study: NCT03760445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: 2.5 mg and 10mg capsules, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: 2.5 mg and 10mg capsules, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: 2.5 mg and 10mg capsules, given orally
Study: NCT01449253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 20 mg initially and then increased to 20 mg TDS if there is no fall in BP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 20 mg initially and then increased to 20 mg TDS if there is no fall in BP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 20 mg initially and then increased to 20 mg TDS if there is no fall in BP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
Study: NCT00505635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 250 mg/m\^2 By Mouth Every 4 Hours x 3 Doses On Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velban
Description: 1.5 mg/m\^2 By Vein Over 15-30 Minutes On Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg/m\^2 By Vein Over 45-120 Minutes On Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 9 MIU/m\^2 By Vein Over 24 Hours x 4 Doses On Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intron-A
Description: 5 mu/m\^2 Subcutaneously (Under the skin) Daily On Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 400 mg By Mouth Daily
Study: NCT01340690

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ω-3 fatty acids suspension
Description: 2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo suspension
Description: suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
Study: NCT04606758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL under fluoroscopic control
Description: Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL under ultrasound control
Description: Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance
Study: NCT02523352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Ventilation
Description: Progressive increase in airway pressure to open lungs atelectatic regions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal catheter positioning
Description: The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
Study: NCT03074500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: Sham taping will be performed without using any technique

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
Study: NCT04433104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells transplantation
Description: Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug therapy according to Vietnamese MOHS procedure
Description: Salbutamol, Terbutaline

Intervention type: DRUG
Group type: OTHER
Intervention: drug therapy according to Vietnamese MOHS procedure
Description: Salbutamol, Terbutaline
Study: NCT02206347

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: attention focus
Study: NCT02313051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT02302274

Intervention type: DRUG
Intervention: flecainide iv
Description: infusion over 10 min
Study: NCT03760445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: 2.5 mg and 10mg capsules, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: 2.5 mg and 10mg capsules, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 20mg or 1000 mg or other strengths as locally available given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 20mg or 1000 mg or other strengths as locally available given intravenously
Study: NCT03567681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Description: Extended release oxcarbazepine vs Immediate release oxcarbazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Description: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Study: NCT03805594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177-PSMA-617
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177-PSMA-617
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177-PSMA-617
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01059331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 mg x 2 daily for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 1 tablet x 2 daily, for 2 days
Study: NCT04333004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Combined With Chemotherapy
Description: Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
Study: NCT01334086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
Study: NCT04331626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injectable Product
Description: Low dose chemotherapy drug combined with pd-1 antibody, Gemcitabine should be administered at 50% of the recommended dose, i.e. 500mg/m2, for 30 minutes by intravenous drip. Day 1 and day 8 administration.